previously

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…

3 weeks ago

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

December 04, 2025 07:00 ET  | Source: Vaxil Bio Ltd. Not for distribution by US newswire or in United States…

3 weeks ago

THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM — PREVIOUSLY SHOWN TO IMPROVE COGNITION — MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE

- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary studies -Key TakeawaysFindings from three NIA-funded ancillary studies to the U.S.…

3 weeks ago

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

September 26, 2025 15:57 ET  | Source: Scilex Holding Company PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) --…

3 months ago

Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective…

4 months ago

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilexs Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a f

June 23, 2025 16:50 ET  | Source: Scilex Holding Company PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex…

6 months ago